Biovie Inc (BIVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biovie Inc (BIVI) has a cash flow conversion efficiency ratio of -0.230x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.44 Million) by net assets ($19.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biovie Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Biovie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Biovie Inc (BIVI) total liabilities for a breakdown of total debt and financial obligations.
Biovie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biovie Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sirona Biochem Corp
V:SBM
|
0.160x |
|
Max Resource Corp
V:MAX
|
-0.139x |
|
Annexin Pharmaceuticals AB
ST:ANNX
|
-0.380x |
|
Energoinstal S.A.
WAR:ENI
|
0.031x |
|
Calibre
PA:ALWIN
|
0.411x |
|
Superior Resources Ltd
AU:SPQ
|
-0.017x |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
N/A |
|
GPM Metals Inc
V:GPM
|
-0.638x |
Annual Cash Flow Conversion Efficiency for Biovie Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Biovie Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Biovie Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $19.01 Million | $-19.03 Million | -1.001x | +44.47% |
| 2024-06-30 | $15.51 Million | $-27.95 Million | -1.802x | +31.32% |
| 2023-06-30 | $15.34 Million | $-40.25 Million | -2.624x | +49.28% |
| 2022-06-30 | $3.67 Million | $-18.99 Million | -5.173x | -149.94% |
| 2021-06-30 | $5.05 Million | $-10.45 Million | -2.070x | -2832.88% |
| 2020-06-30 | $-21.50 Million | $-1.63 Million | 0.076x | +106.45% |
| 2019-06-30 | $2.13 Million | $-2.50 Million | -1.174x | +78.99% |
| 2018-06-30 | $111.20K | $-621.34K | -5.588x | -936.97% |
| 2017-06-30 | $1.16 Million | $-623.62K | -0.539x | -530.93% |
| 2016-06-30 | $1.92 Million | $-163.63K | -0.085x | -107.07% |
| 2015-06-30 | $-54.12K | $-65.38K | 1.208x | +219.80% |
| 2014-06-30 | $171.39K | $-172.83K | -1.008x | -4828.56% |
| 2013-06-30 | $490.70K | $-10.04K | -0.020x | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more